【摘要】 治疗糖尿病的药物在不断更新换代,一味追求昂贵新药的做法并不现实,而应寻求更加具有成本效益、安全的治疗方案。本文通过分析糖尿病治疗中胰岛素起始治疗的时机,并对起始治疗方案进行分析,同时比较了胰岛素类似物、人胰岛素等不同的胰岛素治疗选择,在肯定人胰岛素疗效与安全性的同时,更指出其符合成本效益,可作为适应我国当前经济现状的治疗选择。更多还原

【Abstract】 Newer drugs have been continuously brought to the market during the past years,it is more reasonable to seek for safe and cost-effective therapy rather than expensive new agents,considering the increasing population of diabetic patients and the current socia-economical conditions of our country.This review highly recommended early initiation of insulin therapy by analyzing the timing of insulin initiation and options of insulin products.Different insulin products such as insulin analogue versus recombinant human insulin are compared in terms of efficacy,safety and cost-effectiveness.Conclusion is that human insulin is a cost-effective treatment option better suited to China’s current situation with satisfying safety and efficacy.更多还原